PC
DOVA

Paulson & Co’s Dova Pharmaceuticals, Inc. Common Stock DOVA Stock Holding History

Paulson & Co’s Portfolio DOVA Stock Details DOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-550,681
Closed -$13.2M – 56
2017
Q4 		$13.2M Hold
550,681
– – 0.26% 43
2017
Q3 		$9.98M Sell
550,681
-70,951
-11% -$1.68M 0.18% 44
2017
Q2 		$13.9M Buy
+621,632
New +$13.1M 0.19% 52

Other funds holding DOVA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
PC
Pier Capital Stamford, Connecticut $606M AUM 63.41% 1-Year Est. Return

Paulson & Co's DOVA Position: Q1 2018 in Review

Paulson & Co sold out of Dova Pharmaceuticals, Inc. Common Stock (DOVA) in Q1 2018, closing a stake of 550,681 shares — an estimated $13.2M sold.

Paulson & Co first reported a position in DOVA in Q2 2017 and held it in 3 quarters. The position peaked at $13.9M in Q2 2017. 55 funds tracked by Wall St. Rank hold DOVA as of Q1 2018.

  • Paulson & Co reported no remaining Dova Pharmaceuticals, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Paulson & Co sold 550,681 Dova Pharmaceuticals, Inc. Common Stock shares in Q1 2018, an estimated $13.2M.
  • Paulson & Co first reported a position in Dova Pharmaceuticals, Inc. Common Stock in Q2 2017 and held it in 3 quarters.
  • Paulson & Co's Dova Pharmaceuticals, Inc. Common Stock position peaked at $13.9M in Q2 2017.
  • 55 funds tracked by Wall St. Rank held Dova Pharmaceuticals, Inc. Common Stock as of Q1 2018.

Based on Paulson & Co's 13F filing for Q1 2018, filed 15 May 2018.